Chronic Plaque Psoriasis (Ps) Registry

1. An adult patient (18 years of age or older) with chronic plaque psoriasis who has been prescribed HUMIRA® therapy according to the local product labeling and meets one of the following criteria: * New initiated (within 4 weeks of registry entry) on HUMIRA® therapy; * Initiated HUMIRA® therapy in the past and: * Has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide source documentation of SAEs, AEs, of Special Interest, and dosing information since initiation of therapy. OR * Is entering after participation in an AbbVie HUMIRA (adalimumab) sponsored study and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy after the completion of AbbVie sponsored study and physician can provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of commercial HUMIRA® (defined as a prescribed/non study drug). 2. Patient is willing to consent to data being collected and provided to AbbVie; 3. Patient is capable of and willing to give written informed consent and to comply with the requirements of the registry.

\- Patient should not be enrolled if he/she cannot be treated in accordance with the local product label.